Lonza and bluebird bio, Inc., Establish a Long-term Commercial Manufacturing Agreement for Lenti-D™ and LentiGlobin™ Drug Products Read more about Lonza and bluebird bio, Inc., Establish a Long-term Commercial Manufacturing Agreement for Lenti-D™ and LentiGlobin™ Drug Products
bluebird bio to Present at Goldman Sachs 37th Annual Healthcare Conference Read more about bluebird bio to Present at Goldman Sachs 37th Annual Healthcare Conference
bluebird bio Presents Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting Read more about bluebird bio Presents Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting
bluebird bio Reports First Quarter 2016 Financial Results and Recent Operational Progress Read more about bluebird bio Reports First Quarter 2016 Financial Results and Recent Operational Progress
bluebird bio to Present at Two Upcoming Investor Conferences Read more about bluebird bio to Present at Two Upcoming Investor Conferences
bluebird bio Reports Interim Clinical Data from Starbeam Study of Lenti-D™ at AAN 2016 Annual Meeting Read more about bluebird bio Reports Interim Clinical Data from Starbeam Study of Lenti-D™ at AAN 2016 Annual Meeting
bluebird bio to Present Immuno-Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting Read more about bluebird bio to Present Immuno-Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting
bluebird bio to Present Clinical Data on Lenti-D in CALD in Plenary Session at AAN 2016 Annual Meeting Read more about bluebird bio to Present Clinical Data on Lenti-D in CALD in Plenary Session at AAN 2016 Annual Meeting
bluebird bio to Present at Three Upcoming Investor Conferences Read more about bluebird bio to Present at Three Upcoming Investor Conferences
bluebird bio Announces Transition of Chief Financial Officer Read more about bluebird bio Announces Transition of Chief Financial Officer